Aiping Zhang

Sar, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

DUSP22 dephosphorylates LGALS1 to enhance T cell-driven antitumor immunity.

DUSP22 dephosphorylates LGALS1 to enhance T cell-driven antitumor immunity.

Journal: Journal for immunotherapy of cancer

Published: January 10, 2026

RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion.

RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion.

Journal: Cell death & disease

Published: May 10, 2025

Lymphatic system is the mainstream for breast cancer dissemination and metastasis revealed by single-cell lineage tracing.

Lymphatic system is the mainstream for breast cancer dissemination and metastasis revealed by single-cell lineage tracing.

Journal: Molecular cancer

Published: December 06, 2024

Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy.

Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: December 28, 2023

SB Digestor: a tailored driver gene identification tool for dissecting heterogeneous Sleeping Beauty transposon-induced tumors.

SB Digestor: a tailored driver gene identification tool for dissecting heterogeneous Sleeping Beauty transposon-induced tumors.

Journal: International journal of biological sciences

Published: November 28, 2022

Fueling sentinel node via reshaping cytotoxic T lymphocytes with a flex-patch for post-operative immuno-adjuvant therapy.

Fueling sentinel node via reshaping cytotoxic T lymphocytes with a flex-patch for post-operative immuno-adjuvant therapy.

Journal: Nature communications

Published: June 22, 2022

Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance.

Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance.

Journal: International journal of biological sciences

Published: March 02, 2022

Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing.

Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing.

Journal: Theranostics

Published: June 17, 2021

Patient-Derived Organoids Can Guide Personalized-Therapies for Patients with Advanced Breast Cancer.

Patient-Derived Organoids Can Guide Personalized-Therapies for Patients with Advanced Breast Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: March 23, 2021

S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy.

S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy.

Journal: Nature communications

Published: March 15, 2021

Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy.

Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: March 10, 2021

NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation.

NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation.

Journal: Nature communications

Published: June 11, 2019

Showing 1-12 of 12

Last Updated: 09/26/2026